Farrar, William B.
Mayo Clinic
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Citations 1
Breast Cancer, Version 3.2018
Gradishar, William J. , Anderson, Benjamin O. , Abraham, Jame , Aft, Rebecca , Allison, Kimberly H. , Blair, Sarah L. , Burstein, Harold J. , Dang, Chau T. , Farrar, William B., Goldstein, Lori J. , Isakoff, Steven J. , Lyons, Janice A., Moran, Meena S. , O'Regan, Ruth M., Patel, Sameer A. , Pierce, Lori J. , Reed, Elizabeth , Sitapati, Amy M. , Smith, Mary Lou , Telli, Melinda L. , Shead, Dorothy A. , Goetz, Matthew P. , Elias, Anthony , Giordano, Sharon H. , Marcom, Paul Kelly , Mayer, Ingrid A. , Mortimer, Joanne , Rugo, Hope S. , Smith, Karen L. , Soliman, Hatem Hussein , Ward, John Headley , Young, Jessica S. , Kumar, Rashmi , Telli, Melinda L
Journal of the National Comprehensive Cancer Network | February 20, 2019 | Volume: 17 | Issue: 2 | Pages: 118-126
These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor–positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.